Nestle Health Science enters microbiome research venture

929c1134-8d44-4139-8110-035684bd4b33articleimage.jpg

13 Jul 2017 --- Nestlé Health Science and Enterome are establishing Microbiome Diagnostics Partners (MDP), in an attempt to lead the development and commercialization of innovative microbiome-based diagnostics with the potential to transform therapeutic approaches across health conditions such as inflammatory bowel diseases (IBD) and liver diseases. The partnership follows Nestlé Health Science’s initial investment announced in April 2016.

“Mastering the microbiome is an important facet of our strategy to advance the therapeutic role of nutrition. We also see new opportunities for personalized nutrition both for the healthy population and for patients. The two initial programs have great potential to become differentiated diagnostics,” says Greg Behar, CEO of Nestlé Health Science.

According to the companies, MDP will initially aim to boost Enterome’s diagnostic programs, which include IBD 110 for the assessment and management of mucosal healing and MET210 for NASH (non-alcoholic steatohepatitis). The current standard of care for these conditions include invasive procedures such as endoscopy and biopsies, rather than a non-invasive stool/serum combined Dx tests that will be developed by MDP. Future innovation efforts will leverage advanced microbial and serum-based metabolic technologies developed respectively at Enterome and Nestlé Health Science’s diagnostics arm Prometheus Laboratories.

The companies announced that Microbiome Diagnostics Partners is to be a 50:50 joint venture between Enterome and Nestlé Health Science. Prometheus (a Nestlé Health Science Company) will contribute its Diagnostics (Dx) development and commercialization expertise. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of Dx in all therapeutic areas except immuno-oncology. 

Nestlé Health Science will reportedly invest €20 million in return for its 50 percent stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities.

Commenting on the move, Behar says, “Microbiome Diagnostics Partners is equipped to lead diagnostic discovery in the microbiome field, opening the door to innovative therapeutic approaches combining diagnostics (Dx), nutritional therapies (Nx) and therapeutics (Rx).” 

“The formation of Microbiome Diagnostics Partners is an important milestone for Enterome, as it brings together powerful and complementary technologies and capabilities to enable the creation of a new generation of diagnostic and companion diagnostic products. The MDP joint venture will leverage Enterome’s microbiome-based platforms in diagnostic areas, while Enterome will continue to focus on their application for the discovery of novel small molecule therapeutics,” comments Pierre Belichard, CEO of Enterome.

Related Articles

Nutrition & Health News

Safe use of Olygose GOS supported by new peer-reviewed publications

18 Sep 2017 --- French natural ingredients manufacturer Olygose has announced that new peer-reviewed publications support the safe use of plant-based galacto-oligosaccharides (GOS) from Olygose from infancy to older age.

Nutrition & Health News

Omega 3: A rich source of health benefits and NPD opportunities

11 Sep 2017 --- Omega 3’s benefits keep making the news in the world of nutrition, with the fatty acids’ tight connection to the healthy aging trend just one of the reasons why omega 3 continues to be on the tips of everyone’s tongues.

Nutrition & Health News

Omega 3 boosts gut microbiome diversity

11 Sep 2017 --- Taking omega 3 as part of a healthy diet with plenty of fiber and probiotic foods can improve the diversity of the gut microbiome. This is according to a new study by researchers at the University of Nottingham and King’s College London.

Business News

Vitafoods Asia 2017: Healthy aging, digestive health and personalized nutrition top of mind

28 Aug 2017 --- Healthy aging, digestive health and personalized nutrition will be key areas of focus at this year’s Vitafoods Asia, the event’s organizer, Informa Exhibitions, has announced. During Asia’s only dedicated event for the nutraceutical, functional food and beverages and dietary supplement industries, held on 5 and 6 September, industry experts will uncover the latest innovations and key developments that will impact industry and product development at the Sands Expo and Convention Centre in Marina Bay Sands, Singapore.

Nutrition & Health News

Research sheds new light on link between gut bacteria and anxiety

25 Aug 2017 --- Research published in the open access journal Microbiome has further explained how gut bacteria may influence anxiety-like behaviors by investigating the link between gut bacteria and biological molecules called microRNAs (miRNAs) in the brain.

More Articles
URL : http://www.nutritioninsight.com:80/news/nestle-health-science-enters-microbiome-research-venture.html